Evidence map›Paper›PMID 23473718›Full record

ReviewParkinsonism & related disorders2013

Safety of transcranial magnetic stimulation in Parkinson's disease: a review of the literature.

Matthew Vonloh, Robert Chen, Benzi Kluger

Abstract readReview
In one paragraph

Review in Parkinsonism & related disorders, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Transcranial Ultrasound Stimulation of Internal Globus Pallidus Region and Motor Cortex in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2026
    Trial
  4. Trial
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Non-invasive Brain Stimulation for Central Neuropathic Pain.Frontiers in molecular neuroscience · 2022
    Review
  12. Article
  13. Article
  14. Review
  15. Therapies for Parkinson's diseases: alternatives to current pharmacological interventions.Journal of neural transmission (Vienna, Austria : 1996) · 2016
    Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Matthew VonlohDepartment of Neurology, University of Colorado School of Medicine, Aurora, CO, USA.
Robert Chen
Benzi Kluger

Funding

Colorado Clinical and Translational Sciences InstituteKL2TR001080 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2013 to 2017
$2.6M
Colorado Clinical and Translational Science Institute (KL2)KL2RR025779 · NCRR · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2008 to 2011
$2.2M
Colorado Clinical and Translational Science Institute (KL2)KL2TR000156 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2012 to 2013
$521k
NCATS NIH HHS KL2 TR000156NCATS NIH HHS KL2 TR001080NCRR NIH HHS 5 KL2 RR025779-03NCRR NIH HHS KL2 RR025779
6 · The paper itself

Abstract

backgroundTranscranial magnetic stimulation (TMS) has been used in both physiological studies and, more recently, the therapy of Parkinson's disease (PD). Prior TMS studies in healthy subjects and other patient populations demonstrate a slight risk of seizures and other adverse events. Our goal was to estimate these risks and document other safety concerns specific to PD patients.

methodsWe performed an English-Language literature search through PudMed to review all TMS studies involving PD patients. We documented any seizures or other adverse events associated with these studies. Crude risks were calculated per subject and per session of TMS.

resultsWe identified 84 single pulse (spTMS) and/or paired-pulse (ppTMS) TMS studies involving 1091 patients and 77 repetitive TMS (rTMS) studies involving 1137 patients. Risk of adverse events was low in all protocols. spTMS and ppTMS risk per patient for any adverse event was 0.0018 (95% CI: 0.0002-0.0066) per patient and no seizures were encountered. Risk of an adverse event from rTMS was 0.040 (95% CI: 0.029-0.053) per patient and no seizures were reported. Other adverse events included transient headaches, scalp pain, tinnitus, nausea, increase in pre-existing pain, and muscle jerks. Transient worsening of Parkinsonian symptoms was noted in one study involving rTMS of the supplementary motor area (SMA).

conclusionWe conclude that current TMS and rTMS protocols do not pose significant risks to PD patients. We would recommend that TMS users in this population follow the most recent safety guidelines but do not warrant additional precautions.

Indexed as

Databases, BibliographicHumansParkinson DiseaseTranscranial Magnetic Stimulation

Identifiers

PMID23473718
PMCPMC3653978

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.